Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy
Details
Publication Year 2024-04,Volume 311,Issue #1,Page e231703
Journal Title
Radiology
Publication Type
Review
Abstract
There is increasing demand worldwide to develop diagnostic and therapeutic (theranostic) markers for prostate cancer. One target of interest is prostate-specific membrane antigen (PSMA), a protein which is overexpressed in prostate cancer cells. Over the past decade, a growing body of literature has demonstrated that radiolabeled ligands that target PSMA show favorable clinical response and survival outcomes in patients with advanced prostate cancer. This focused review provides background to the development of PSMA as a target, an overview of key studies informing our current approach to radioligand-based imaging and therapy for prostate cancer, and a model for real-world implementation of PSMA theranostics based on an Australian experience.
Publisher
Radiological Society of North America
Keywords
Male; Humans; *Precision Medicine; Prostate; Australia; *Prostatic Neoplasms/diagnostic imaging/therapy; Pelvis
Department(s)
Cancer Imaging
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-11 01:39:07
Last Modified: 2024-07-11 01:47:52

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙